Research Topics
Genomes and Genes
| William PaoSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A protein knockdown strategy to study the function of beta-catenin in tumorigenesisFeng Cong
Program in Cell Biology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
BMC Mol Biol 4:10. 2003..Aberrant Wnt signaling, which results from mutations of either beta-catenin or adenomatous polyposis coli (APC), renders beta-catenin resistant to degradation, and has been associated with multiple types of human cancers...
Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenanceWilliam Pao
Departments of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Proc Natl Acad Sci U S A 100:8764-9. 2003....
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directionsWilliam Pao
Program in Cancer Biology and Genetics and the Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
J Clin Oncol 23:2556-68. 2005..Here, we present current knowledge about EGFR mutations in the context of clinical trials involving gefitinib and erlotinib in NSCLC...- Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainWilliam Pao
Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
PLoS Med 2:e73. 2005..Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance... - KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibWilliam Pao
Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
PLoS Med 2:e17. 2005..Lung adenocarcinomas also harbor activating mutations in the downstream GTPase, KRAS, and mutations in EGFR and KRAS appear to be mutually exclusive... - EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinibWilliam Pao
Program in Cancer Biology and Genetics and Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Proc Natl Acad Sci U S A 101:13306-11. 2004..Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity... - Defining clinically relevant molecular subsets of lung cancerWilliam Pao
Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 125, New York, NY 10021, USA
Cancer Chemother Pharmacol 58:s11-5. 2006..We are now using a variety of molecular and biological approaches to help further define molecular subsets of lung cancer that have relevance in the clinic... - 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC)William Pao
Department of Medicine and Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 62, New York, NY 10021, USA
Semin Cancer Biol 14:33-40. 2004..Whether EGFR is required for the maintenance of lung tumor survival is also discussed. Finally, strategies to identify predictors of response to gefitinib are explored... - Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancerLucia Regales
Pao Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Invest 119:3000-10. 2009..Moreover, this approach could serve as an important model for targeting other receptor tyrosine kinases activated in human cancers... 
Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelinesNicolas Girard
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Chest 137:46-52. 2010..Here, we report on seven patients in whom epidermal growth factor receptor (EGFR) and Kirsten-rat sarcoma 2 viral oncogene homolog (KRAS) tumor mutation status was used to determine clonal relationships among multiple lung lesions...- Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinomaJames Bean
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 14:7519-25. 2008..We aimed to identify additional second-site alterations associated with acquired resistance... - EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expressionAllan R Li
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
J Mol Diagn 10:242-8. 2008..Thus, these results indicate that EGFR amplification, preferentially of the mutant allele, often accompanies EGFR mutation, whereas EGFR immunohistochemical staining associates with amplification but cannot predict EGFR mutation status... - Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastasesNicolas Girard
Pao Lab, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Am J Surg Pathol 33:1752-64. 2009..Given its high correlation with molecular characterization of such tumors, it may provide a much cheaper and faster method to address this problem... - A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutationsGregory J Riely
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York City, New York, USA
J Thorac Oncol 6:1435-7. 2011..Salirasib prevents Ras membrane binding thereby blocking the function of all Ras isoforms. This phase II study determined the activity of salirasib in patients with advanced lung adenocarcinomas with KRAS mutations... - EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinibJuliann Chmielecki
Weill Cornell Graduate School of Medical Sciences, New York, New York, USA
J Thorac Oncol 7:434-42. 2012..We explored whether all EGFR TKIs similarly select for the T790M mutation using data from early clinical trials and established in vitro models of acquired resistance... - Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4Jenifer L Marks
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 2:e426. 2007..We performed mutational profiling of a large cohort of lung adenocarcinomas to uncover other potential somatic mutations in genes of this signaling pathway that could contribute to lung tumorigenesis... - Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancerKatharine A Price
Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York City, New York, USA
J Thorac Oncol 5:1623-9. 2010..This phase II trial assessed the efficacy of the combination of gefitinib and everolimus in patients with advanced NSCLC... - Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinibGregory J Riely
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 12:839-44. 2006..We undertook this study to explore the relationship between EGFR mutation type and clinical variables, including treatment with gefitinib and erlotinib... - Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitorsMarissa N Balak
Human Oncology and Pathogenesis Program, Thoracic Oncology Service, Varmus Lab, Department of Pathology, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
Clin Cancer Res 12:6494-501. 2006..Collectively, our data suggest that the type and nature of kinase inhibitor resistance mutations may be influenced by both anatomic site and mode of binding to the kinase target... - Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitorsLucia Regales
Pao Lab, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 2:e810. 2007..The EGFR T790M mutation confers acquired resistance to kinase inhibitors in human EGFR mutant lung adenocarcinoma, is occasionally detected before treatment, and may confer genetic susceptibility to lung cancer... - Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinibVincent A Miller
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Howard Building, Room 1012, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 26:1472-8. 2008..We conducted this phase II trial to determine the efficacy of erlotinib in patients with bronchioloalveolar carcinoma (BAC) and adenocarcinoma, BAC subtype, and to determine molecular characteristics associated with response... - Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignanciesSelvaraju Veeriah
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Nat Genet 42:77-82. 2010..These data strongly point to PARK2 as a tumor suppressor on 6q25.2-q27. Thus, PARK2, a gene that causes neuronal dysfunction when mutated in the germline, may instead contribute to oncogenesis when altered in non-neuronal somatic cells... - Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutationsYelena Y Janjigian
Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York City, New York, USA
J Thorac Oncol 6:569-75. 2011..Whether treatment with TKI improves outcomes in patients with resected lung adenocarcinoma and EGFR mutation is unknown... - Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysisStephen B Solomon
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 118, New York, NY 10021, USA
AJR Am J Roentgenol 194:266-9. 2010.... - Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinibMaureen F Zakowski
Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
Arch Pathol Lab Med 133:470-7. 2009..A subset of lung adenocarcinomas appears preferentially sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). EGFR-activating mutations and never smoking are associated with response to TKIs... - Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutationGeoffrey R Oxnard
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York 10065, USA
Clin Cancer Res 17:1616-22. 2011..In half of these cases, a second EGFR mutation, T790M, underlies acquired resistance. We undertook this study to examine the clinical course of patients harboring the T790M mutation following progression on TKI... - Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancerDaniel T Milton
Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York, USA
Cancer 110:599-605. 2007..A phase 1 study was conducted of the combination of everolimus, an mTOR inhibitor, and gefitinib to determine a daily dose of everolimus with gefitinib in patients with advanced nonsmall-cell lung cancer (NSCLC)... - Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinibYelena Y Janjigian
Gastrointestinal and Thoracic Oncology Services, Division of Solid Tumor Oncology, Department of Medicine and Radiology, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
Clin Cancer Res 17:2521-7. 2011..To evaluate the toxicity and efficacy of cetuximab and erlotinib in patients with acquired resistance to erlotinib, we conducted this phase I/II clinical trial... - Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomasDuyKhanh Pham
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 24:1700-4. 2006..Investigators have reported an association between EGFR mutations and the amount and duration of cigarette smoking, with the highest incidence of mutations seen in never smokers... - Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1Kadoaki Ohashi
Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
Proc Natl Acad Sci U S A 109:E2127-33. 2012.... - Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinibGeoffrey R Oxnard
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA
Clin Cancer Res 17:6322-8. 2011..To better understand these results, we studied the natural history of lung cancers which recurred despite adjuvant TKI... - High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507)Yixuan Gong
Pao Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS ONE 4:e7273. 2009..The IGF receptor type 1 (IGF-1R) pathway is frequently deregulated in human tumors and has become a target of interest for anti-cancer therapy... - Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary reportNicolas Girard
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 16:755-63. 2010..We hypothesized that we could use the Internet to bolster the accrual of appropriate patients... - Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayMaria E Arcila
Molecular Diagnostics Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 17:1169-80. 2011..Using high sensitivity methods, the T790M is detected in up to 68% of these patients... - Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinibMelissa L Johnson
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
J Thorac Oncol 6:1128-31. 2011..The SRC inhibitor dasatinib demonstrates antitumor activity in gefitinib-resistant cells lines and xenografts. Dasatinib is tolerable for patients with advanced non-small cell lung cancer, and in combination with erlotinib... - Molecular on/off switchDaniel T Milton
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weil Medical College of Cornell University, New York, NY, USA
J Clin Oncol 24:4940-2. 2006 - Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinomaJenifer L Marks
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Thorac Oncol 3:111-6. 2008..Whether EGFR and KRAS mutations also have an impact on survival in patients who undergo lung resection for curative intent in the absence of targeted therapy has not been established... - Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimusGregory J Riely
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 13:5150-5. 2007..In these patients, we sought to assess changes in tumor metabolism and size after stopping and restarting erlotinib or gefitinib and to determine the effect of adding everolimus... - A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancerDaniel T Milton
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and the Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 107:1034-41. 2006..The 5% objective response rate did not reach the stated objective at the interim efficacy analysis, prompting the closure of the study... - Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR geneNaiyer A Rizvi
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York 10021, USA
Clin Cancer Res 17:3500-6. 2011..To determine if tumor regression following treatment with gefitinib correlates with the presence of sensitizing mutations in epidermal growth factor receptor (EGFR)... - Screening for germline EGFR T790M mutations through lung cancer genotypingGeoffrey R Oxnard
Thoracic Oncology Service and Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Thorac Oncol 7:1049-52. 2012..We hypothesized that patients with lung cancers found to harbor the EGFR T790M resistance mutation before treatment, an uncommon occurrence, would be likely to carry underlying germline T790M mutations... - "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancerChristian Grommes
Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Neuro Oncol 13:1364-9. 2011..Pulsatile erlotinib can control CNS metastases from EGFR mutant lung cancer after failure of standard daily dosing. CNS disease may not harbor acquired resistance mutations that develop systemically. A prospective trial is planned... - Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01Andrew B Lassman
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Clin Cancer Res 11:7841-50. 2005.... - A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker developmentBinsheng Zhao
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 16:4647-53. 2010.... - Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoiseChristopher G Azzoli
Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10021, USA
J Thorac Oncol 3:84-93. 2008..This paper will review the molecular markers which are having immediate impact on treatment decisions in routine practice, and which merit further study in the next generation of adjuvant chemotherapy trials... - Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomasYixuan Gong
Pao Laboratory, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
PLoS Med 4:e294. 2007..We sought to improve understanding of this process in order to provide insight into mechanisms of sensitivity and/or resistance to tyrosine kinase inhibitors and to uncover new targets for therapy... - Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingJuliann Chmielecki
Weill Cornell Graduate School of Medical Sciences, New York, NY 10021, USA
Sci Transl Med 3:90ra59. 2011..This modeling predicted alternative therapeutic strategies that could prolong the clinical benefit of TKIs against EGFR-mutant NSCLCs by delaying the development of resistance... - MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibJames Bean
Human Oncology and Pathogenesis Program, Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Proc Natl Acad Sci U S A 104:20932-7. 2007..Taken together, these data suggest that MET amplification occurs independently of EGFR(T790M) mutations and that MET may be a clinically relevant therapeutic target for some patients with acquired resistance to gefitinib or erlotinib... - Practical management of patients with non-small-cell lung cancer treated with gefitinibNeelam T Shah
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J Clin Oncol 23:165-74. 2005..CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib... - High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancerJennifer L Clarke
Department of Neurology and Brain Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
J Neurooncol 99:283-6. 2010..However, intermittent (pulsatile) high dose administration (1000-1500 mg/week) achieves a higher CSF concentration than standard dosing, and successfully controlled LM in this patient... - Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinomaGregory J Riely
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 14:5731-4. 2008..These mutations are predictive of poor prognosis in resected disease as well as resistance to treatment with erlotinib or gefitinib... - KRAS mutations in non-small cell lung cancerGregory J Riely
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Proc Am Thorac Soc 6:201-5. 2009..In this review, we summarize the initial discovery of RAS mutations in NSCLC, describe work exploring associations with clinical factors and outcomes, and provide an overview of current approaches to targeting KRAS mutant NSCLC... - Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasSizhi Paul Gao
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
J Clin Invest 117:3846-56. 2007..Therefore, mutant EGFR could activate the gp130/JAK/STAT3 pathway by means of IL-6 upregulation in primary human lung adenocarcinomas, making this pathway a potential target for cancer treatment... - Lung adenocarcinoma: guiding EGFR-targeted therapy and beyondMarc Ladanyi
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Mod Pathol 21:S16-22. 2008.... - Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancerWilliam Pao
Department of Medicine, Vanderbilt Ingram Cancer Center, 2220 Pierce Avenue, 777 Preston Research Building, Nashville, Tennessee 37232 6307, USA
Nat Rev Cancer 10:760-74. 2010..This Review summarizes recent developments aimed at treating and ultimately curing the disease... - Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomasNicolas Girard
Human Oncology and Pathogenesis Program HOPP, Weill Medical College of Cornell University, New York, New York, USA
Clin Cancer Res 15:6790-9. 2009..However, whether the underlying biology of these tumors warrants such clustering is unclear, and the optimum treatment of either entity is unknown... - Genetic predictors of MEK dependence in non-small cell lung cancerChristine A Pratilas
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer Res 68:9375-83. 2008.... - Integration of molecular profiling into the lung cancer clinicWilliam Pao
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Clin Cancer Res 15:5317-22. 2009..Implementation will facilitate realization of the promise of molecularly tailored therapy, which could lead to more effective treatments with fewer side effects... - Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomasQiulu Pan
Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Mol Diagn 7:396-403. 2005..These assays offer higher sensitivity and ease of scoring and eliminate the need for sequencing, providing a robust and accessible approach to the rapid identification of most lung cancer patients likely to respond to EGFR inhibitors... - Update on epidermal growth factor receptor mutations in non-small cell lung cancerGregory J Riely
Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 12:7232-41. 2006..Although a tremendous amount of knowledge has been gained in the past 2 years, there remain a number of important epidemiologic, biological, and clinical questions... - Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancersNicolas Girard
Pao Lab, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 15:5184-90. 2009..Decisions are currently made using the Martini and Melamed criteria, which are mostly based on tumor location and histologic type. New genomic tools could improve the ability to assess tumor clonality... - Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinomaJenifer L Marks
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Cancer Res 68:5524-8. 2008..MEK1 mutants have not previously been reported in lung cancer and may provide a target for effective therapy in a small subset of patients with lung adenocarcinoma... - Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancerVincent A Miller
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
J Clin Oncol 22:1103-9. 2004..Phase II trials suggested female sex and adenocarcinoma were associated with response. We undertook this analysis to identify additional clinical and pathologic features associated with sensitivity to gefitinib... - The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancersSelvaraju Veeriah
Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
Proc Natl Acad Sci U S A 106:9435-40. 2009..PTPRD was found to dephosphorylate the oncoprotein STAT3. These results implicate PTPRD as a tumor suppressor on chromosome 9p that is involved in the development of GBMs and multiple human cancers... - Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptorsKaterina Politi
Program in Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Genes Dev 20:1496-510. 2006..These models may be useful for developing improved therapies for patients with lung cancers bearing EGFR mutations... - Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?Gregory J Riely
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer Biol Ther 4:1096-7. 2005 - Constitutive activation of Raf-1 induces glioma formation in miceYelena Lyustikman
Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Neoplasia 10:501-10. 2008..Our study suggests that the oncogenic effect of KRas in glioma formation may be transduced at least in part through Raf signaling and that therapeutic targeting of this pathway may be beneficial in glioma treatment... - BAC consensus conference, November 4-6, 2004: epidemiology, pathogenesis, and preclinical modelsDavid C Christiani
Harvard University Schools of Medicine and Public Health, Boston, MA, USA
J Thorac Oncol 1:S2-7. 2006..CONCLUSIONS: Elucidation of molecular events involved in BAC tumorigenesis will allow for more precise epidemiologic studies and improved animal models, which will enable development of more effective treatments against the disease... - Characterizing the cancer genome in lung adenocarcinomaBarbara A Weir
Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Nature 450:893-8. 2007..More generally, our results indicate that many of the genes that are involved in lung adenocarcinoma remain to be discovered... - Serum levels of surfactant protein D are increased in mice with lung tumorsFeijie Zhang
National Jewish Medical and Research Center, Denver, Colorado 80206, USA
Cancer Res 63:5889-94. 2003..In conclusion, serum SP-D concentration is increased in mice bearing lung tumors and generally reflects the tumor burden but is also elevated during lung inflammation... - Erlotinib in lung cancerWilliam Pao
N Engl J Med 353:1739-41; author reply 1739-41. 2005 - Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapyChih Hsin Yang
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
J Clin Oncol 26:2745-53. 2008..To explore predictive factors for time to treatment failure (TTF) in chemotherapy-naive non-small-cell lung cancer (NSCLC) patients receiving gefitinib treatment... - EGFR mutant lung adenocarcinomas in patients with germline BRCA mutationsJenifer L Marks
J Thorac Oncol 3:805. 2008 - Somatic mutations affect key pathways in lung adenocarcinomaLi Ding
The Genome Center at Washington University, Department of Genetics, Washington University School of Medicine, St Louis, Missouri 63108, USA
Nature 455:1069-75. 2008..Our findings shed further light on several important signalling pathways involved in lung adenocarcinoma, and suggest new molecular targets for treatment... - Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?William Pao
J Natl Cancer Inst 96:1117-9. 2004 - Epidermal growth factor receptor mutations detected in tumors from Chinese "never smokers" with lung adenocarcinomaGuo-ping Ren
Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Chin Med J (Engl) 118:769-71. 2005 - Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesTodd A Carter
Ambit, Inc, 4215 Sorrento Valley Boulevard, San Diego, CA 92121, USA
Proc Natl Acad Sci U S A 102:11011-6. 2005.... - Monitoring EGFR-mutant lung cancers by means of the bloodWilliam Pao
J Thorac Oncol 1:199-200. 2006 - Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal methodWilliam Pao
Clin Cancer Res 13:4954-5. 2007
Research Grants
- Overcoming acquired resistance to EGFR inhibitors in lung cancerWilliam Pao; Fiscal Year: 2007....
- Elucidating Mechanisms of Lung Tumor RegressionWilliam Pao; Fiscal Year: 2007..The long-range goal is to identify molecular targets to induce apoptosis in human lung cancers. ..